Acanthosis nigricans - I-Acanthosis Nigricans
☆ AI Dermatology — Free Service
Kwiziphumo zika-2022 ze-Stiftung Warentest ezivela eJamani, ukwaneliseka kwabathengi ngeModelDerm bekungaphantsi kancinci kunokubonisana nge-telemedicine ehlawulweyo.
Kwiziphumo zika-2022 ze-Stiftung Warentest ezivela eJamani, ukwaneliseka kwabathengi ngeModelDerm bekungaphantsi kancinci kunokubonisana nge-telemedicine ehlawulweyo.
Ixhaphakile kubantu abatyebe kakhulu.
relevance score : -100.0%
ReferencesAcanthosis nigricans kukubonakaliswa kwesikhumba semeko ephantsi. Ihlala ibonakala kwimiphetho yesikhumba njengentamo, amakhwapha, kunye ne-groin, ikhangeleka njengamabala amnyama anemiphetho engacacanga. Le meko idla ngokunxulunyaniswa ne‑diabetes mellitus kunye nokunganyangeki kwe‑insulin resistance, kodwa kwiimeko ezinqabileyo, inokukhomba i‑internal malignancy. Isenikubonakala ngenxa ye‑hormone disorders okanye ekuthatheni amayeza athile anje nge‑systemic glucocorticoids kunye ne‑oral contraceptives.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans (AN) yimeko yolusu eqhelekileyo edityaniswe kwimiba eyahlukeneyo yezempilo njengokunganyaniseka kwe‑insulin (insulin resistance), isifo seswekile (diabetes mellitus), ukutyeba (obesity), umhlaza ongaphakathi (internal malignancy), iingxaki zehomoni (hormone disorders), kunye nokusabela kumayeza (drug reactions). Ukunyanga i‑AN kugxile ekujonganeni neengxaki zempilo ezisisiseko. Ekuqaleni, oogqirha bahlola iimpawu ze‑insulin resistance syndrome, okubandakanya ukutyeba, i‑cholesterol ephezulu, uxinzelelo lwegazi oluphezulu, kunye nohlobo lwe‑2 yeswekile. Oogqirha bahlala bechaza i‑retinoid ezisetyenziselwa ukutyhila (topical retinoids) njengokhetho lokuqala lonyango, olunokunceda ngokujiya kwesikhumba. Nangona kunjalo, abanakho ukujongana ngokupheleleyo nobumnyama bolusu. Ezinye iindlela zonyango (i‑asidi ye‑salicylic (salicylic acid), i‑podophyllin, i‑urea, i‑calcipotriol) nazo zifuna ukusetyenziswa rhoqo.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
○ Izizathu
Ngokuqhelekileyo kwenzeka kubantu abangaphantsi kweminyaka engama-40 ubudala, banokuba nemfuzo kwaye inxulunyaniswa nokutyeba kakhulu okanye i-endocrinopathies, njenge-hypothyroidism, i-acromegaly, isifo se-polycystic ovary, isifo seswekile esinganyangekiyo kwi-insulin okanye isifo sikaCushing.
○ Unyango ― OTC Amachiza
#40% urea cream